33 related articles for article (PubMed ID: 30181170)
1. Tovorafenib effective against low-grade gliomas harbouring BRAF fusions.
Sidaway P
Nat Rev Clin Oncol; 2024 Feb; 21(2):83. PubMed ID: 38082106
[No Abstract] [Full Text] [Related]
2. Braf Mutations Initiate the Development of Rat Gliomas Induced by Postnatal Exposure to N-Ethyl-N-Nitrosourea.
Wang Q; Satomi K; Oh JE; Hutter B; Brors B; Diessl N; Liu HK; Wolf S; Wiestler O; Kleihues P; Koelsch B; Kindler-Röhrborn A; Ohgaki H
Am J Pathol; 2016 Oct; 186(10):2569-76. PubMed ID: 27658714
[TBL] [Abstract][Full Text] [Related]
3. Targeting All
Bhamidipati D; Pellatt A; Subbiah V
JCO Precis Oncol; 2024 Feb; 8():e2300670. PubMed ID: 38380848
[TBL] [Abstract][Full Text] [Related]
4. Advances in the treatment of BRAF-mutant low-grade glioma with MAPK inhibitors.
Houghton PJ
Transl Pediatr; 2024 Mar; 13(3):513-517. PubMed ID: 38590382
[No Abstract] [Full Text] [Related]
5. BRAF/MEK inhibitors use to treat ventriculoperitoneal shunt-associated ascites in pediatric low-grade gliomas.
Amayiri N; Obeidat M; Laban DA; Musharbash A; Al-Hussaini M; Maraqa B; Ibrahimi A; Sarhan N; Bouffet E
Pediatr Blood Cancer; 2024 May; ():e31058. PubMed ID: 38753385
[No Abstract] [Full Text] [Related]
6. Corrigendum to: A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas.
Neuro Oncol; 2024 May; 26(5):985-986. PubMed ID: 38521609
[No Abstract] [Full Text] [Related]
7. BRAF V600E-mutated diffuse glioma in an adult patient: a case report and review.
Suzuki Y; Takahashi-Fujigasaki J; Akasaki Y; Matsushima S; Mori R; Karagiozov K; Joki T; Ikeuchi S; Ikegami M; Manome Y; Murayama Y
Brain Tumor Pathol; 2016 Jan; 33(1):40-9. PubMed ID: 26445861
[TBL] [Abstract][Full Text] [Related]
8. A Secondary Mutation in
Wang J; Yao Z; Jonsson P; Allen AN; Qin ACR; Uddin S; Dunkel IJ; Petriccione M; Manova K; Haque S; Rosenblum MK; Pisapia DJ; Rosen N; Taylor BS; Pratilas CA
Cancer Discov; 2018 Sep; 8(9):1130-1141. PubMed ID: 29880583
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology.
Hatae R; Hata N; Suzuki SO; Yoshimoto K; Kuga D; Murata H; Akagi Y; Sangatsuda Y; Iwaki T; Mizoguchi M; Iihara K
Neuropathology; 2017 Jun; 37(3):191-199. PubMed ID: 27792249
[TBL] [Abstract][Full Text] [Related]
10. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
[TBL] [Abstract][Full Text] [Related]
11. To BRAF or not to BRAF: is that even a question anymore?
Horbinski C
J Neuropathol Exp Neurol; 2013 Jan; 72(1):2-7. PubMed ID: 23242278
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas.
Lassaletta A; Zapotocky M; Mistry M; Ramaswamy V; Honnorat M; Krishnatry R; Guerreiro Stucklin A; Zhukova N; Arnoldo A; Ryall S; Ling C; McKeown T; Loukides J; Cruz O; de Torres C; Ho CY; Packer RJ; Tatevossian R; Qaddoumi I; Harreld JH; Dalton JD; Mulcahy-Levy J; Foreman N; Karajannis MA; Wang S; Snuderl M; Nageswara Rao A; Giannini C; Kieran M; Ligon KL; Garre ML; Nozza P; Mascelli S; Raso A; Mueller S; Nicolaides T; Silva K; Perbet R; Vasiljevic A; Faure Conter C; Frappaz D; Leary S; Crane C; Chan A; Ng HK; Shi ZF; Mao Y; Finch E; Eisenstat D; Wilson B; Carret AS; Hauser P; Sumerauer D; Krskova L; Larouche V; Fleming A; Zelcer S; Jabado N; Rutka JT; Dirks P; Taylor MD; Chen S; Bartels U; Huang A; Ellison DW; Bouffet E; Hawkins C; Tabori U
J Clin Oncol; 2017 Sep; 35(25):2934-2941. PubMed ID: 28727518
[TBL] [Abstract][Full Text] [Related]
13. BRAF Dimerization: An Underlying Resistance Mechanism in Low-Grade Pediatric Gliomas.
Romano G; Kwong LN
Cancer Discov; 2018 Sep; 8(9):1064-1065. PubMed ID: 30181170
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]